Nektar Therapeutics’ (NKTR) “Market Perform” Rating Reaffirmed at William Blair
William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report […]
William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report […]
